SLAMF1 and B-cell chronic lymphocytic leukemia: Our studies not only broaden the knowledge about CD150 and CD180 involvement in CLL pathobiology, but also suggest additional receptor-directed approaches for improvement of CLL patients’ survival and quality of life.